SIMILARITIES AND DIFFERENCES IN TREATMENT PATTERNS AND RESOURCE UTILISATION FOR MULTIPLE MYELOMA: A COMPARISON BETWEEN 4 NORDIC COUNTRIES

被引：0
|
作者：
Persson, S. [1 ]
Ghatnekar, O. [1 ]
Liwing, J. [2 ]
Aschan, J. [2 ]
Mellqvist, U. H. [3 ]
机构：
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Janssen Cilag AB, Sollentuna, Sweden
[3] Dept Hematol, Gothenburg, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72189-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A42 / A42
页数：1
相关论文
共 50 条
  • [41] Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response
    Park, Ho Young
    Kim, Kyung Won
    Yoon, Min A.
    Lee, Min Hee
    Chae, Eun Jin
    Lee, Jeong Hyun
    Chung, Hye Won
    Yoon, Dok Hyun
    CANCER IMAGING, 2020, 20 (01)
  • [42] CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH CARE RESOURCE UTILIZATION AMONG ITALIAN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY
    Palumbo, A.
    Zagorska, A.
    Popov, S.
    Zyczynski, T.
    Davis, C.
    Di Rienzo, P.
    HAEMATOLOGICA, 2016, 101 : 595 - 595
  • [43] Real-World Treatment Patterns, Outcomes, Health Care Resource Utilization and Cost Burden of Multiple Myeloma in South Korea Using the National Claims Data
    Park, YoungJu
    Park, Sung Soo
    Yoon, Soomin
    Jeong, Jihyeon
    Lee, Doik
    Kim, Kihyun
    BLOOD, 2023, 142
  • [44] RESOURCE UTILISATION AND RELATED HEALTH CARE COSTS AMONG PATIENTS WITH MULTIPLE MYELOMA WITH ≥ 2 PRIOR LINES OF TREATMENT IN FINLAND: EVALUATION BASED ON FINNISH REAL WORLD DATA FROM AURIA BIOBANK
    Kosunen, M.
    Kurki, S.
    Snicker, K.
    Wiik, E.
    VALUE IN HEALTH, 2017, 20 (09) : A498 - A499
  • [45] Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Systeme National des Donnees de Sante (SNDS) database: a retrospective cohort study
    Bessou, Antoine
    Colin, Xavier
    De Nascimento, Julie
    Sopwith, Will
    Ferrante, Shannon
    Gorsh, Boris
    Gutierrez, Benjamin
    Sansbury, Leah
    Willson, Jenny
    Sapra, Sandhya
    Paka, Prani
    Wang, Feng
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (03): : 321 - 333
  • [46] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and Lanreotide for the treatment of neuroendocrine tumors (NET)
    Lynn Huynh
    Cai, Beilei
    Lejeune, Dominique
    Cheng, Mu
    Lax, Angie
    Duh, Mei S.
    Cheng, Wendy
    Kim, Michelle K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 134 - 134
  • [47] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).
    Huynh, Lynn
    Cai, Beilei
    Sharperson, Camara
    Lejeune, Dominique
    Duh, Mei Sheng
    Kim, Michelle Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] A COMPARISON BETWEEN 4-AMINOPYRIDINE AND 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF MULTIPLE-SCLEROSIS
    BERTELSMANN, FW
    POLMAN, CH
    VANDIEMEN, HAM
    DEWAAL, R
    KOETSIER, JC
    ANNALS OF NEUROLOGY, 1992, 32 (02) : 256 - 256
  • [49] Multiple myeloma incidence, mortality, and survival differences at the intersection of sex, age, and race/ethnicity: A comparison between Puerto Rico and the United States SEER population
    Castaneda-Avila, Maira A.
    Suarez-Ramos, Tonatiuh
    Torres-Cintron, Carlos R.
    Epstein, Mara M.
    Gierbolini-Bermudez, Axel
    Tortolero-Luna, Guillermo
    Ortiz-Ortiz, Karen J.
    CANCER EPIDEMIOLOGY, 2024, 89
  • [50] TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS) IN GERMANY TREATED WITH NABIXIMOLS BETWEEN 2010 AND 2020
    Freilich, J.
    Rodriguez-Rey, M. Delclaux
    Braune, S.
    Spelman, T.
    Yeramaneni, S.
    Drachenberg, C.
    VALUE IN HEALTH, 2022, 25 (12) : S123 - S123
12345